Resources Repository
-
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Mathematical Models | Technology Assessment | Europe | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Global | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Mathematical Models | Technology Assessment | Europe | Preferences/Values | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology | North America -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Mathematical Models | State-Transition | Asia & Pacific | Health Outcomes | Dynamic Transmission | Microsimulation | Infectious Diseases | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2010Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately …
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Motivated by the global recommendation by the WHO that all countries include infant rotavirus vaccination in their national immunization programs, the objective of this analysis was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. The authors synthesized population-level data from various sources (primarily from…
Mathematical Models | State-Transition | Asia & Pacific | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2010Model Uncertainty in Economic Evaluation of Health Interventions: Rotavirus Vaccination in Vietnam
Motivated by observed discrepancies between 2 published studies on the cost-effectiveness of rotavirus vaccination in …
Motivated by observed discrepancies between 2 published studies on the cost-effectiveness of rotavirus vaccination in Vietnam, the authors' objectives were to illustrate a specific, systematic approach to assessing model (structure and process) uncertainty and to quantify explicitly the contributions of different sources of variation in the outputs of different studies that share the same research question. On the basis of a series of working definitions of key model elements, the authors developed 5 alternative computer…
Mathematical Models | State-Transition | Asia & Pacific | Calibration/Validation | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Mathematical Models | Europe | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2023Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual …
The National Institute for Health and Care Excellence (NICE) updated its Health Technology Evaluation manual in 2022, merging processes from all 4 Health Technology Evaluation programs into a single document. Key changes include introducing a new disease severity modifier while maintaining existing methods on health inequality, discounting, unrelated healthcare costs, and value of information. Changes were categorized by importance, with most being modest updates or clarifications aligning with existing principles. The methods involved a 2-stage…
Technology Assessment | Europe | Health/Medicine -
ArticlePublication 2010Alternative Strategies to Reduce Maternal Mortality in India: A Cost-Effectiveness Analysis
This article, published in PLoS Medicine, conducted a cost-effectiveness analysis of strategies to improve pregnancy …
This article, published in PLoS Medicine, conducted a cost-effectiveness analysis of strategies to improve pregnancy and childbirth safety in India. Country- and region-specific data were synthesized using a computer-based model that simulates the natural history of pregnancy and pregnancy-associated complications in individual women, and considers delivery location, attendant, and facility level. Model validation compared projected maternal indicators with empiric data. Strategies consisted of improving coverage of effective interventions that could be provided individually or packaged…
Mathematical Models | Asia & Pacific | Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
State-Transition | Europe | Value of Information | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | North America